Talwar Puneet, Sinha Juhi, Grover Sandeep, Agarwal Rachna, Kushwaha Suman, Srivastava M V Padma, Kukreti Ritushree
Academy of Scientific and Innovative Research (AcSIR), CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) Campus, New Delhi, India; Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), Delhi, India.
Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), Delhi, India.
J Neurol Sci. 2016 Jan 15;360:179-87. doi: 10.1016/j.jns.2015.12.004. Epub 2015 Dec 3.
The possible association between Apolipoprotein E (ApoE) levels in the cerebrospinal fluid (CSF) and Alzheimer's disease (AD) has been studied extensively. However, previous findings have been inconsistent. We conducted a meta-analysis of observational studies, seeking to provide insights into ApoE's potential as a biomarker for AD. A systematic literature search of PubMed (MEDLINE), EMBASE, and Web of Science was performed to retrieve relevant studies evaluating ApoE levels in CSF from AD subjects and controls. The association between ApoE levels in the CSF and AD was estimated by the weighted mean difference (WMD) and 95% confidence interval (CI) using a random-effect model. We identified 24 studies that included 1064AD cases and 1338 non-demented controls. Although the pooled WMD did not indicate a significant association between AD and ApoE levels (-0.30mg/l; 95% CI: -0.69 to 0.09; P=0.13), sub-group analysis controlling for patient sample size (n≥43) revealed significantly lower ApoE levels (WMD: -0.66mg/l; 95% CI: -1.02 to -0.31; P=0.0002) among patients with AD than in controls. Publication bias was absent and sensitivity analysis did not result in any significant change in the pooled estimates, indicating highly stable results. The present meta-analysis indicates the potential of CSF ApoE levels as a predictor of AD association.
脑脊液（CSF）中载脂蛋白E（ApoE）水平与阿尔茨海默病（AD）之间可能存在的关联已得到广泛研究。然而，先前的研究结果并不一致。我们对观察性研究进行了荟萃分析，旨在深入了解ApoE作为AD生物标志物的潜力。通过对PubMed（MEDLINE）、EMBASE和Web of Science进行系统的文献检索，以检索评估AD患者和对照者脑脊液中ApoE水平的相关研究。使用随机效应模型，通过加权平均差（WMD）和95%置信区间（CI）来估计脑脊液中ApoE水平与AD之间的关联。我们确定了24项研究，其中包括1064例AD病例和1338例非痴呆对照。尽管合并的WMD未表明AD与ApoE水平之间存在显著关联（-0.30mg/l；95%CI：-0.69至0.09；P=0.13），但对患者样本量（n≥43）进行控制的亚组分析显示，AD患者的ApoE水平显著低于对照组（WMD：-0.66mg/l；95%CI：-1.02至-0.31；P=0.0002）。不存在发表偏倚，敏感性分析也未导致合并估计值发生任何显著变化，表明结果高度稳定。本荟萃分析表明脑脊液ApoE水平作为AD关联预测指标的潜力。
